It was recently reported that a very worthy company was awarded an additional round of funding, thus putting them into a “unicorn” status. Named Tempus, this is a cancer-fighting firm that recently was awarded additional funding. And because of this, their value is now worth approximately $2billion dollars, according to the company’s co-founder and CEO, Eric Lefkofsky. Being over a billion dollars put them in an “unicorn” status, and not that many start-ups can claim they are worth over a billion dollars.
More About Tempus
Established a few years ago, Tempus was created when it was observed that the health care system was not using data that may have been valuable towards the treatment of patients suffering from cancer. This sort of situation really hit home when a loved one of Lefkofsky had been suffering from cancer.
Nevertheless, since this company’s inception, it has been making huge strides in using genomic data to better treat cancer patients. Located in Chicago, Illinois, Tempus has already grown significantly with the hiring of a bigger and stronger labor force to more aggressively work with enriched genomic data that goes a long way for cancer treatment. Before the last funding amount received which is around $80 million, they received around $70 million. In this case, they hired 400 employees, approximating around 30 more employees added monthly. And now they are planning on hiring even more labor force, especially in the data and tech fields at their company.
The Co-founder and CEO
Originally from a suburb outside of Detroit, Michigan, Lefkofsky is a serial entrepreneur and businessman. He began his entrepreneurship early on, and he also earned a bachelor of arts degree and a Juris Doctorate degree from the University of Michigan.